Dyadic Applied BioSolutions

Following our strategic rebrand, Dyadic Applied BioSolutions has published an updated investor presentation that reflects our strategic transition from a research driven organization to a commercially focused enterprise. Powered by our patented fungal protein production platforms, we're advancing applied solutions, delivering high-value, input proteins and enzymes for the , , , and industrial sectors.

Check out our presentation on the website to learn more about our strategic transition:https://d2ghdaxqb194v2.cloudfront.net/2606/197950.pdf

Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity

https://dyadic.com/dyadic-announced-an-mou-with-bangladeshs-state-owned-pharmaceutical-company-to-facilitate-biopharmaceutical-research-and-biomanufacturing-capacity/

We want to welcome Dyadic International, Inc International, Inc. (NASDAQ: $DYAI) to the ROTH Capital Partners 35th Annual Conference (March 12–14) section of B2i Digital at https://lnkd.in/ezkbqYDD

Dyadic International (Nasdaq: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.

Dyadic’s primary area of focus is on applying its industrially proven fungus Thermothelomyces heterothallica to speed development, lower costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets.

Additionally, Dyadic is further developing the Dapibus™ filamentous fungal based microbial protein production platform for the development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.

Dyadic is leveraging its microbial platform technologies to enable collaborators to develop effective preventative and therapeutic treatments in developed and emerging countries.

To learn more about the Dyadic C1 Technology, please visit www.dyadic.com.

We look forward to seeing the continued results from Mark Emalfarb, Ronen Tchelet, Ping Wang Rawson, Joe Hazelton the rest of the Dyadic International, Inc. team!

Dyadic (NASDAQ:DYAI) management speaks with Proactive Investors regarding the dosing in Phase 1 clinical trial DYAI-100 booster vaccine candidate

Dyadic International starts dosing in Phase 1 clinical trial DYAI-100 booster vaccine candidate Dyadic International CEO Mark Emalfarb and Chief Business Officer Joe Hazelton joined Steve Darling from Proactive to share news the company has announced a ...